Endoscopic Fundoplication Versus Proton Pump Inhibitors for GERD Treatment (TvP)
A Randomized Controlled Trial of Transoral Incisionless Fundoplication (TIF) Versus Proton Pump Inhibitors (PPIs) for Treatment of GERD: The TIF vs. PPIs Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Limburg
-
Maastricht, Limburg, Netherlands, 6229 HX
- University Hospital Maastricht
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18-75 years
- Proven gastroesophageal reflux (pH < 4 for > 4.3% time while off PPIs for 7-14 days)
- On daily PPIs for > 1 year
- Recurrence of GERD symptoms (GERD-HRQL score difference of > 10 between on and off PPIs)
- Normal or hypotonic LES resting pressure (5-40 mmHg)
- Patient willingness to cooperate with random group assignment, attend 4-5 office visits and comply with all tests in this protocol
- Signed informed consent
Exclusion Criteria:
- BMI > 35
- Hiatal hernia > 2 cm
- Esophagitis grade D
- Barrett's esophagus
- Esophageal stricture
- Esophageal ulcer
- Esophageal motility disorder
- Gastric motility disorder
- Prior splenectomy
- Gastric paralysis
- Pregnancy (in females)
- Immunosuppression
- ASA > 2
- Portal hypertension
- Coagulation disorders
- Previous antireflux procedure
- Any other health condition, which the investigator believes would prevent the patient from completing the study
- Lack of fluency in English
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: EsophyX
|
The TIF procedure using the EsophyX system with SerosaFuse fasteners was designed to create full-thickness serosa-to-serosa plications and construct valves of 3-5 cm in length and 200-300° in circumference.
Other Names:
|
|
Active Comparator: Proton Pump Inhibitors
|
Proton Pump Inhibitors; active control
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
GERD symptoms
Time Frame: Baseline
|
Baseline
|
|
GERD symptoms
Time Frame: 6 month follow-up
|
6 month follow-up
|
|
GERD symptoms
Time Frame: 12 month follow-up
|
12 month follow-up
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PPI usage
Time Frame: at 0, 6 and 12 month follow- up
|
at 0, 6 and 12 month follow- up
|
|
|
Lower esophageal acid exposure
Time Frame: at 0, 6 and 12 month follow- up
|
at 0, 6 and 12 month follow- up
|
|
|
Esophagitis
Time Frame: at 0, 6 and 12 month follow- up
|
Percentage of Participants with Esophagitis (Los Angeles classification scale)
|
at 0, 6 and 12 month follow- up
|
|
Rate of adverse events
Time Frame: at 0, 6 and 12 month follow- up
|
at 0, 6 and 12 month follow- up
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Blair A Jobe, MD, University of Pittsburgh Medical Center
- Principal Investigator: Nicole D Bouvy, MD, PhD, University Hospital Maastricht, The Netherlands
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Gastrointestinal Diseases
- Esophageal Motility Disorders
- Deglutition Disorders
- Esophageal Diseases
- Gastroesophageal Reflux
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Gastrointestinal Agents
- Anti-Ulcer Agents
- Rabeprazole
- Omeprazole
- Esomeprazole
- Pantoprazole
- Proton Pump Inhibitors
Other Study ID Numbers
Other Study ID Numbers
- D00668-01C
- PRO08110069 (Other Identifier: University of Pittsburgh)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.